Literature DB >> 7649305

C-type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: interaction with ANF-R2/ANP-C receptors.

P Savoie1, J de Champlain, M B Anand-Srivastava.   

Abstract

C-type natriuretic peptide (CNP) and brain natriuretic peptide (BNP) are members of the natriuretic peptide family, which have been shown to interact with ANP-C/ANF-R2 receptors in addition to ANP-B receptor subtypes. The present study was undertaken to investigate if the interaction of CNP and BNP with ANP-C receptors results in the inhibition of adenylyl cyclase activity. CNP and BNP inhibited adenylyl cyclase activity in heart and brain striatal membranes in a concentration dependent manner with an apparent Ki between 0.1 and 1.0 nM. Maximal inhibition observed in heart membranes were about 25% and 35% for BNP and CNP respectively, however the inhibitions in brain striatal membranes were smaller (approximately 20%). The inhibition was dependent on the presence of guanine nucleotides and was attenuated by pertussis toxin treatment. In addition, CNP inhibited the stimulatory effect of isoproterenol on adenylyl cyclase, whereas CNP as well as BNP showed an additive effect with the inhibitory response of angiotensin II on adenylyl cyclase activity. When the combined effect of C-ANF4-23/BNP, C-ANF4-23/CNP and BNP/CNP at optimal concentrations was studied together on adenylyl cyclase activity, the percent inhibition remained the same for C-ANF4-23 and BNP or C-ANF4-23 and CNP, however, an additive inhibitory effect was observed for BNP and CNP. These results suggest that CNP and BNP like C-ANF4-23 interact with ANP-C receptors and result in the inhibition of adenylyl cyclase activity. On the other hand, CNP and BNP interact with the ANP-C receptor, however, the interaction may be different sites or there may be two subpopulations of ANP-C receptors specific for each of the peptides. These results indicate that BNP and CNP, like ANP and C-ANF4-23, inhibit the adenylyl cyclase/cAMP signal transduction system through an inhibitory guanine nucleotide regulatory protein, by interacting with ANP-C receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649305     DOI: 10.1016/0014-5793(95)00780-d

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  NPR-C: a component of the natriuretic peptide family with implications in human diseases.

Authors:  Speranza Rubattu; Sebastiano Sciarretta; Angelica Morriello; Camilla Calvieri; Allegra Battistoni; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2010-06-19       Impact factor: 4.599

3.  Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension.

Authors:  J Marcil; M B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

Review 4.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

5.  BNP facilitates NMB-encoded histaminergic itch via NPRC-NMBR crosstalk.

Authors:  Qing-Tao Meng; Xian-Yu Liu; Xue-Ting Liu; Juan Liu; Admire Munanairi; Devin M Barry; Benlong Liu; Hua Jin; Yu Sun; Qianyi Yang; Fang Gao; Li Wan; Jiahang Peng; Jin-Hua Jin; Kai-Feng Shen; Ray Kim; Jun Yin; Ailin Tao; Zhou-Feng Chen
Journal:  Elife       Date:  2021-12-17       Impact factor: 8.140

6.  Atrial natriuretic peptide regulates Ca channel in early developmental cardiomyocytes.

Authors:  Lin Miao; Min Wang; Wen-Xuan Yin; Qi Yuan; Ying-Xiao Chen; Bernd Fleischmann; Jürgen Hescheler; Guangju Ji
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

Review 7.  Recent advances in natriuretic peptide research.

Authors:  Geoffrey E Woodard; Juan A Rosado
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.